MARKET

AIMT

AIMT

Aimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.86
+1.05
+7.09%
After Hours: 16.14 +0.28 +1.73% 17:48 04/08 EDT
OPEN
15.07
PREV CLOSE
14.81
HIGH
16.42
LOW
14.87
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
37.00
52 WEEK LOW
10.09
MARKET CAP
1.03B
P/E (TTM)
-3.9943
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AIMT stock price target is 43.20 with a high estimate of 66.00 and a low estimate of 21.00.

EPS

AIMT News

More
  • Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
  • Business Wire · 9h ago
  • Should You Avoid Aimmune Therapeutics Inc (AIMT)?
  • Insider Monkey · 1d ago
  • Aimmune: On Sale After Coronavirus Crash
  • Seeking Alpha - Article · 03/31 14:03
  • Independent Director Patrick Enright Just Bought Shares In Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
  • Simply Wall St. · 03/22 13:06

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About AIMT

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
More

Webull offers kinds of Aimmune Therapeutics Inc stock information, including NASDAQ:AIMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIMT stock news, and many more online research tools to help you make informed decisions.